2025•SSRN Electronic JournalOpen access

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 Trial

Salomon Manier, Jérôme Lambert, Cyrille Hulin, Margaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederic Orsini Piocelle, Mamoun Dib, Laurence Sanhès, Pierre Morel, Abderazzak El Yamani, Mourad Tiab, Reza Tabrizi, Valentine Richez, Laurent Garderet, Bruno Royer, Benoît Bareau, Clara Mariette, Emmanuel Fleck, Daniela Robu, Claire Calmettes, Sophie Rigaudeau, Hélène Demarquette, Laurent Frenzel, Olivier Decaux, Mohamad Mohty, Bertrand Arnulf, Aurore Perrot, Jill Corre, Jean‐Yves Mary, Hervé Avet‐Loiseau, Philippe Moreau, Xavier P Leleu, Thierry T.F. Facon

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Daratumumab, Lenalidomide, Regimen, Dexamethasone, Multiple myeloma, Medicine, Oncology, Internal medicine